Tag: Iheezo
Harrow, Inc. partners with Apotex Inc. to enhance Canadian eyecare market
In a landmark development for the Canadian healthcare industry, Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc., Canada's largest pharmaceutical ... Read More
Novartis to offload US rights to five ophthalmic drugs to Harrow
Harrow Health, an ophthalmic therapies developer, will acquire the exclusive US commercial rights to five FDA‑approved ophthalmic products from the Novartis group of companies for ... Read More
Harrow Health announces IHEEZO FDA approval for ocular surface anesthesia
IHEEZO FDA approval : Harrow Health, a Nasdaq-listed eyecare pharmaceutical company, and Sintetica have secured approval for IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% from the ... Read More